Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.

Tira Jing Ying Tan Sarah L Sammons Young-Hyuck Im Lilin She Kelly Mundy Robert Bigelow Tiffany A Traina Carey K Anders Joe Poh Sheng Yeong Ezequiel Renzulli Sung-Bae Kim Rebecca A Dent

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

PFS was longer than expected with both regimens. A patient subset with wild-type BRCA platinum-sensitive aTNBC had durable disease control with chemotherapy-free maintenance.

Keyphrases

phase ii
wild type
clinical trial
open label
locally advanced
phase iii
placebo controlled
study protocol